Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT03620123 2022-11-18

OPTIM

Phase 2 Completed

54 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Phase 1/2 Unknown

13 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03132038 2022-01-11

NISCAHN

Phase 2 Completed

98 enrolled

Head & Neck

Neoplasm Metastasis, Recurrence, Salivary Gland Neoplasms

NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Phase 2 Withdrawn

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

PRiME II

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

HESTIA

GlitIpNi

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

LOGICAN

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

OPTIM

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

NISCAHN

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)